TNF-alpha Inhibitors, Most Notably Humira and Remicade, Will Continue to Dominate the Crohn's Disease Drug Market

TNF-alpha Inhibitors, Most Notably Humira and Remicade, Will Continue to
Dominate the Crohn's Disease Drug Market
Continued Uptake of Humira Will be the Greatest Contributor to Market Growth
Over the Next Five Years, According to a New Report from Decision Resources

WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's
leading research and advisory firms for pharmaceutical and healthcare issues,
finds that, in the Crohn's disease drug market, the dominance of TNF-alpha
inhibitors such as Abbott/Eisai's Humira and Centocor Ortho
Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the
next decade. Sales of Humira and Remicade, which accounted for more than
three-quarters of the market in 2008, will continue to grow through 2018 in
the United States, France, Germany, Italy, Spain, the United Kingdom and
Japan.

The new Pharmacor report entitled Crohn's Disease finds that, although several
emerging therapies with novel mechanisms of action are expected to launch over
the next decade, none will rival the efficacy - or the dominant market share -
of the TNF-alpha inhibitors. Owing to increasing physician familiarity with
these agents and continuing emergence of favorable post-marketing clinical
trial data, TNF-alpha sales will total nearly $2.5 billion in 2018. The report
also finds that the 2008 launches in the U.S. of Biogen Idec/Elan's Tysabri
and UCB/Otsuka's Cimzia had a negligible impact on the Crohn's disease market.
Both agents will remain relegated to second- or later-line biological therapy
through 2018, behind both Humira and Remicade.

"The continued uptake of Humira will be the greatest contributor to market
growth over the next five years," said Decision Resources Analyst Benjamin
Guikema, Ph.D. "This is due to physician familiarity with the drug and
increasing patient preference for Humira due to its convenient subcutaneous
dosing."

The report also finds that the Crohn's disease drug market will be driven
largely by increasing sales of maintenance therapies, while, in contrast,
sales of acute therapies will remain flat through 2018. However, as there is
no current therapy that is completely effective in maintaining remission of
the disease, significant opportunity remains for the development of
more-effective maintenance therapies.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at
www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Decision Resources, Inc.
Christopher Comfort Elizabeth Marshall
781-296-2597 781-296-2563
ccomfort@dresources.com emarshall@dresources.com

SOURCE Decision Resources

Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com